We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology

News   Nov 19, 2010

 
Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology
 
 
 

RELATED ARTICLES

Targeted Photodynamic Therapy Stops Tumor Growth in 70% of Mice

News

A team of scientists has experimentally proved the effectiveness of the formerly suggested "light" method in oncotherapy. In a series of laboratory preclinical tests, the tumor growth stopped in 70% of mice.

READ MORE

Blindness Prevented in Animal Models of Retinal Degeneration

News

Using a novel patient-specific stem cell-based therapy, blindness was prevented in animal models of geographic atrophy, the advanced 'dry' form of age-related macular degeneration (AMD), which is a leading cause of vision loss among people age 65 and older.

READ MORE

Breast Cancer Survivors Report Improvements in Side Effects After Acupressure

News

Breast cancer survivors reported improvements in depression, pain, anxiety and sleep after self-administered acupressure.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE